微信直播

WCLC 2017专访 | Dr. Mari Mino-Kenudson:活检领域的困难及未来发展方向

Published at: 2015年第1卷第S1期

AME
关键词:

编者按:2017年10月15日-18日,由国际肺癌研究联合会举办的第18届世界肺癌大会于日本美丽的港口都市横滨圆满召开。此次学术盛会吸引了全世界众多从事肺癌研究,临床工作,预防控制领域的专家学者关注和参会。来自美国马塞诸塞州综合医院病理科主任Dr. Mari Mino-Kenudso在会上以“Appropriate and Optimized Handling of Biopsy or Cytology Specimens”为题进行了分享。我们有幸采访到她(图1),近距离“取经”,了解她对活检现状及未来发展的看法。

人物聚焦:Mari Mino-Kenudson

Department of Pathology, Massachusetts General Hospital, Boston, USA

Dr. Mino-Kenudson is Associate Professor of Pathology at Harvard Medical School. She and her team have described the morphology of molecularly annotated and/or biologically aggressive lung adenocarcinomas. They were the first group to report the signet ring cell morphology associated with ALK rearranged lung adenocarcinoma, as well as tumor islands, which associate with KRAS mutations and unfavorable patient outcomes, and are now considered to represent airspace invasion. She and her collaborators have also been actively investigating resistant mechanisms for EGFR and ALK tyrosin kinase inhibitors that will aid in identifying appropriate treatment for those patients after development of resistance to the inhibitors. She has contributed to the 2015 WHO classification of lung tumours and is a member of the Pathology Panel of the International Association for the Study of Lung Cancer (IASLC).

图1. Dr. Mari Mino-Kenudso(左)和AME编辑(右)合影留念

在采访中,Dr. Mino-Kenudson告诉我们,目前在肺癌领域中,活检面临的主要问题是“僧多粥少”。对肺癌患者实行个性化用药需要病理医生用组织样本进行多种检测,比如说,需要进行组织亚型的测试来确定组织学疗法,需要进行分子检测来检测基因突变,还需进行PD-L1免疫组化检测,确认患者是否适合免疫疗法。然而,组织切片样本小,数量少,给病理医生的工作增添了难度,他们需要尽量减少样本浪费,充分利用样本以完成多种检测。Dr. Mino-Kenudson认为,充分利用组织样本进行有效的检测是非常重要的。检测的结果直接影响了治疗方案的选择,也就是说,这是影响患者命运的。她认为医生不应该错过给患者予有效治疗的任何机会。

此外,Dr. Mino-Kenudson还分享了对液体活检的看法。她认为技术每时每刻都在进步,虽然现在液体活检的敏感性仍不理想,但是在不久的将来也许可以应用液体活检进行多种检测,惠及更多肺癌患者。

更多精彩内容,请观看下方视频。

  1. As personalized medicine was brought up along with minimally invasive endoscopic technology in the field of lung cancer, what kinds of complexities they have brought to the handling of tissue samples?

  2. Why are appropriate and optimized handling of biopsy or cytology specimens so important?

  3. What are the challenges in handling of biopsy or cytology specimens?

  4. What could we expect from future developments?


采访编辑:刘小妹,AME Publishing Company

写作编辑:李肖梅,AME Publishing Company

视频编辑:麦雪芳,AME Publishing Company

comments powered by Disqus

附件